129 related articles for article (PubMed ID: 35731258)
1. A phase Ib study of Oraxol (oral paclitaxel and encequidar) in patients with advanced malignancies.
Ma WW; Li JJ; Azad NS; Lam ET; Diamond JR; Dy GK; Opyrchal M; Zhi J; Kramer D; Chan WK; Cutler D; Kwan R; Adjei AA; Jimeno A
Cancer Chemother Pharmacol; 2022 Jul; 90(1):7-17. PubMed ID: 35731258
[TBL] [Abstract][Full Text] [Related]
2. Phase I/II Study of Weekly Oraxol for the Second-Line Treatment of Patients With Metastatic or Recurrent Gastric Cancer.
Lee KW; Lee KH; Zang DY; Park YI; Shin DB; Kim JW; Im SA; Koh SA; Yu KS; Cho JY; Jung JA; Bang YJ
Oncologist; 2015 Aug; 20(8):896-7. PubMed ID: 26112004
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers.
Chon HS; Kang S; Lee JK; Apte SM; Shahzad MM; Williams-Elson I; Wenham RM
BMC Cancer; 2017 Jun; 17(1):407. PubMed ID: 28595616
[TBL] [Abstract][Full Text] [Related]
4. A Phase 1 Dose-Escalation Study of Low-Dose Metronomic Treatment With Novel Oral Paclitaxel Formulations in Combination With Ritonavir in Patients With Advanced Solid Tumors.
de Weger VA; Vermunt MAC; Stuurman FE; Burylo AM; Damoiseaux D; Hendrikx JJMA; Sawicki E; Moes JJ; Huitema ADR; Nuijen B; Rosing H; Mergui-Roelvink M; Beijnen JH; Marchetti S
Clin Pharmacol Drug Dev; 2021 Jun; 10(6):607-621. PubMed ID: 33021083
[TBL] [Abstract][Full Text] [Related]
5. A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignancies.
Chow LQ; Jonker DI; Dy GK; Nicholas G; Fortin C; Patricia D; Adjei AA; Belani CP; Gupta A; Park JS; Zhang S; Sbar EI; Laurie SA
Cancer Chemother Pharmacol; 2013 May; 71(5):1273-85. PubMed ID: 23468081
[TBL] [Abstract][Full Text] [Related]
6. TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies.
Burris HA; Kurkjian CD; Hart L; Pant S; Murphy PB; Jones SF; Neuwirth R; Patel CG; Zohren F; Infante JR
Cancer Chemother Pharmacol; 2017 Aug; 80(2):261-273. PubMed ID: 28601972
[TBL] [Abstract][Full Text] [Related]
7. A Phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours.
van Herpen CM; Eskens FA; de Jonge M; Desar I; Hooftman L; Bone EA; Timmer-Bonte JN; Verweij J
Br J Cancer; 2010 Oct; 103(9):1362-8. PubMed ID: 20877350
[TBL] [Abstract][Full Text] [Related]
8. Oral paclitaxel and encequidar in patients with breast cancer: a pharmacokinetic, safety, and antitumor activity study.
Dai MS; Chao TC; Chiu CF; Lu YS; Shiah HS; Jackson CGCA; Hung N; Zhi J; Cutler DL; Kwan R; Kramer D; Chan WK; Qin A; Tseng KC; Hung CT; Chao TY
Ther Adv Med Oncol; 2023; 15():17588359231183680. PubMed ID: 37492633
[TBL] [Abstract][Full Text] [Related]
9. A dose regimen-finding study to evaluate the safety, tolerability, pharmacokinetics, and activity of oratecan in subjects with advanced malignancies.
Boland PM; Fountzilas C; Fakih M; Opyrchal M; Diamond JR; Corr B; Ma WW; Redman M; Chan WK; Wang H; Kramer D; Kwan R; Cutler D; Zhi J; Jimeno A
Cancer Chemother Pharmacol; 2022 Aug; 90(2):175-187. PubMed ID: 35904620
[TBL] [Abstract][Full Text] [Related]
10. Oral paclitaxel with encequidar compared to intravenous paclitaxel in patients with advanced cancer: A randomised crossover pharmacokinetic study.
Jackson CGCA; Hung T; Segelov E; Barlow P; Prenen H; McLaren B; Hung NA; Clarke K; Chao TY; Dai MS; Yeh HT; Cutler DL; Kramer D; He J; Zhi J; Chan WK; Kwan R; Deva S
Br J Clin Pharmacol; 2021 Dec; 87(12):4670-4680. PubMed ID: 33960504
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors.
Pauer LR; Olivares J; Cunningham C; Williams A; Grove W; Kraker A; Olson S; Nemunaitis J
Cancer Invest; 2004; 22(6):886-96. PubMed ID: 15641487
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics for oral paclitaxel in patients with advanced/metastatic solid tumors.
He J; Jackson CGCA; Deva S; Hung T; Clarke K; Segelov E; Chao TY; Dai MS; Yeh HT; Ma WW; Kramer D; Chan WK; Kwan R; Cutler D; Zhi J
CPT Pharmacometrics Syst Pharmacol; 2022 Jul; 11(7):867-879. PubMed ID: 35470967
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies.
Appleman LJ; Beumer JH; Jiang Y; Lin Y; Ding F; Puhalla S; Swartz L; Owonikoko TK; Donald Harvey R; Stoller R; Petro DP; Tawbi HA; Argiris A; Strychor S; Pouquet M; Kiesel B; Chen AP; Gandara D; Belani CP; Chu E; Ramalingam SS
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1289-1301. PubMed ID: 31549216
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours.
Suder A; Ang JE; Kyle F; Harris D; Rudman S; Kristeleit R; Solca F; Uttenreuther-Fischer M; Pemberton K; Pelling K; Schnell D; de Bono J; Spicer J
Eur J Cancer; 2015 Nov; 51(16):2275-84. PubMed ID: 26296295
[TBL] [Abstract][Full Text] [Related]
15. First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors.
Li T; LoRusso P; Maitland ML; Ou SH; Bahceci E; Ball HA; Park JW; Yuen G; Tolcher A
J Hematol Oncol; 2016 Mar; 9():23. PubMed ID: 26966027
[TBL] [Abstract][Full Text] [Related]
16. A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies.
du Bois A; Huober J; Stopfer P; Pfisterer J; Wimberger P; Loibl S; Reichardt VL; Harter P
Ann Oncol; 2010 Feb; 21(2):370-375. PubMed ID: 19889612
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors.
Sweeney CJ; Chiorean EG; Verschraegen CF; Lee FC; Jones S; Royce M; Tye L; Liau KF; Bello A; Chao R; Burris HA
J Clin Oncol; 2010 Oct; 28(29):4513-20. PubMed ID: 20837944
[TBL] [Abstract][Full Text] [Related]
18. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B
Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459
[TBL] [Abstract][Full Text] [Related]
19. Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results.
Heath EI; Blumenschein GR; Cohen RB; Lorusso PM; Loconte NK; Kim ST; Ruiz-Garcia A; Chao RC; Wilding G
Cancer Chemother Pharmacol; 2011 Sep; 68(3):703-12. PubMed ID: 21140147
[TBL] [Abstract][Full Text] [Related]
20. SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer.
Gonzalez-Angulo AM; Krop I; Akcakanat A; Chen H; Liu S; Li Y; Culotta KS; Tarco E; Piha-Paul S; Moulder-Thompson S; Velez-Bravo V; Sahin AA; Doyle LA; Do KA; Winer EP; Mills GB; Kurzrock R; Meric-Bernstam F
J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25688104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
